Dronedarone

Publication date: Available online 19 March 2016 Source:Cardiac Electrophysiology Clinics Author(s): Rafik Tadros, Stanley Nattel, Jason G. AndradeTeaser Dronedarone is the newest antiarrhythmic drug approved for the maintenance of sinus rhythm in patients with nonpermanent atrial fibrillation (AF). It is a multi-channel blocker with diverse electrophysiologic properties. Dronedarone decreases the incidence of AF recurrence and the ventricular rate during recurrence. Dronedarone decreases rates of cardiovascular hospitalizations in patients with paroxysmal and persistent AF. Dronedarone increases mortality in patients with permanent AF and those with moderate-severe heart failure, and should thus be avoided in these populations. Dronedarone is less effective than amiodarone but also has less toxicity. Direct comparison with other antiarrhythmic drugs is not available.
Source: Cardiac Electrophysiology Clinics - Category: Cardiology Source Type: research